A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Pfizer

Status: Completed

Conditions: Multiple Myeloma

Treatments: Drug: Elranatamab; Drug: Standard of care

Study type: Observational

Funder types: Industry

Identifiers

NCT05932290

C1071031

Details and patient eligibility

About

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from multiple real-world sources, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.

Enrollment: 514 patients

Sex: All

Ages: 18+ weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years and older at index date
• Diagnosis of MM
• Measurable disease according to IMWG criteria
• ECOG performance status ≤2
• Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory [TCR])
• At least 1 treatment following their TCR eligibility

Exclusion criteria

• Acute plasma cell leukemia
• Amyloidosis
• Smoldering MM
• Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
• Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
• Administration with an investigational drug within 30 days prior to index

Trial design

514 participants in 2 patient groups

Elranatamab

Description:

Patients treated with elranatamab from the MagnetisMM-3 trial

Treatment:

Drug: Elranatamab

Standard of care

Description:

Patients treated with standard-of-care therapies from real-world data sources

Treatment:

Drug: Standard of care